Myeloma is unique among the hematologic malignancies in its capacity to cause bone destruction. However, bone-resorbing cytokines that are responsible for the bone destruction in patients have not been identified. Recently, we found that myeloma cells in culture produce low amounts of bone-resorbing cytokines unless cocultured with marrow stromal cells or treated with soluble VCAM-1 receptor which mediates cell-to-cell interactions between myeloma cells and stromal cells. These results indicate the importance of the bone environment in the behavior of myeloma. Based on these observations, we hypothesize that: (1) Myeloma cells produce excess bone-resorbing cytokines when in direct contact with marrow stromal cells; (2) This cell- to-cell interaction is mediated by VCAM-1 expressed by marrow stromal cells and by alpha4Beta1 integrin expressed by myeloma cells; and (3) The production of these cytokines is important not just for the bone destruction, but also for further progression of the malignancy. To test these hypotheses, we will: (1) Determine the importance of the cell attachment molecules VCAM-1 and alpha4Beta1 integrin in vivo in our murine and human models of myeloma bone disease using neutralizing antibodies we have available to VCAM-1 and to alpha4beta1. In addition, we will determine in bone sections from our models of myeloma bone disease and in marrow biopsy sections from patients with myeloma, if myeloma cells and marrow stromal cells bind via VCAM-1 and alpha4beta1 integrin using immunohistochemical analyses with antibodies against these moieties that react with both human and murine VCAM-1 and alpha4beta1; (2) Determine the role that Rank ligand plays in myeloma bone disease; (3) Determine the known cytokines expressed by murine myeloma cells cocultured with stromal cells or by VCAM-1 treated myeloma cells by treating the conditioned media with neutralizing antibodies to osteoclast- activating cytokines. If osteoclastogenic cytokines are identified which we cannot neutralize with antibodies to the known cytokines, we will clone, identify and characterize these unknown bone-resorbing cytokines using an expression cloning approach.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA040035-16
Application #
6587808
Study Section
Project Start
2002-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
16
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Arnold Egloff, Shanna A; Du, Liping; Loomans, Holli A et al. (2017) Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget 8:722-741
Arnold, Shanna A; Loomans, Holli A; Ketova, Tatiana et al. (2016) Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis 33:29-44
Preston Campbell, J; Mulcrone, P; Masood, S K et al. (2015) TRIzol and Alu qPCR-based quantification of metastatic seeding within the skeleton. Sci Rep 5:12635
Sharma, Ramaswamy; Williams, Paul J; Gupta, Anjana et al. (2015) A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, ?-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. Oncotarget 6:21589-602
Seeley, Erin H; Wilson, Kevin J; Yankeelov, Thomas E et al. (2014) Co-registration of multi-modality imaging allows for comprehensive analysis of tumor-induced bone disease. Bone 61:208-16
Johnson, Rachelle W; Merkel, Alyssa R; Page, Jonathan M et al. (2014) Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis 31:945-59
Ding, Hao; Nyman, Jeffry S; Sterling, Julie A et al. (2014) Development of Raman spectral markers to assess metastatic bone in breast cancer. J Biomed Opt 19:111606
Hansen, Amanda G; Arnold, Shanna A; Jiang, Ming et al. (2014) ALCAM/CD166 is a TGF-?-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res 74:1404-15
Waning, David L; Mohammad, Khalid S; Guise, Theresa A (2013) Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror. Cancer Cell 24:407-9
Jin, Renjie; Sterling, Julie A; Edwards, James R et al. (2013) Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS One 8:e60983

Showing the most recent 10 out of 210 publications